CN112826926A - Preparation method of diabetes improving medicine based on manganese type antioxidant enzyme - Google Patents
Preparation method of diabetes improving medicine based on manganese type antioxidant enzyme Download PDFInfo
- Publication number
- CN112826926A CN112826926A CN202110269038.9A CN202110269038A CN112826926A CN 112826926 A CN112826926 A CN 112826926A CN 202110269038 A CN202110269038 A CN 202110269038A CN 112826926 A CN112826926 A CN 112826926A
- Authority
- CN
- China
- Prior art keywords
- powder
- antioxidant enzyme
- diabetes
- preparation
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 17
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 14
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 14
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 14
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 13
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229910052748 manganese Inorganic materials 0.000 title claims abstract description 12
- 239000011572 manganese Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 42
- 239000000463 material Substances 0.000 claims abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 238000002156 mixing Methods 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 7
- 229920001353 Dextrin Polymers 0.000 claims abstract description 7
- 239000004375 Dextrin Substances 0.000 claims abstract description 7
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 7
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 7
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 claims abstract description 7
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 claims abstract description 7
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 claims abstract description 7
- 235000019425 dextrin Nutrition 0.000 claims abstract description 7
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 7
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 7
- 239000000600 sorbitol Substances 0.000 claims abstract description 7
- 229940013618 stevioside Drugs 0.000 claims abstract description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019202 steviosides Nutrition 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000000265 homogenisation Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000009811 Momordica charantia Nutrition 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 3
- 235000008708 Morus alba Nutrition 0.000 claims description 3
- 240000001949 Taraxacum officinale Species 0.000 claims description 3
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 3
- 244000078912 Trichosanthes cucumerina Species 0.000 claims description 3
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 3
- 240000008042 Zea mays Species 0.000 claims description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 3
- 235000005822 corn Nutrition 0.000 claims description 3
- 238000000465 moulding Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 210000004153 islets of langerhan Anatomy 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 6
- 206010054044 Diabetic microangiopathy Diseases 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 201000009101 diabetic angiopathy Diseases 0.000 abstract description 3
- 210000003038 endothelium Anatomy 0.000 abstract description 3
- 230000024883 vasodilation Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000011506 response to oxidative stress Effects 0.000 description 4
- 230000003064 anti-oxidating effect Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 101100366137 Mesembryanthemum crystallinum SODCC.1 gene Proteins 0.000 description 1
- 101100096142 Panax ginseng SODCC gene Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 101150017120 sod gene Proteins 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of diabetes treatment, and particularly relates to a preparation method of a diabetes improving drug based on manganese type antioxidant enzyme, which comprises the following steps: the method comprises the following steps: placing oat-beta glucan and sorbitol into a homogenizer for homogenization; step two: adding fructus Momordicae Charantiae powder, stigma Maydis, radix Puerariae powder, folium Mori powder, herba Taraxaci powder, rhizoma Polygonati powder and superoxide dismutase MnSOD into the homogenized material, stirring and mixing; step three: filtering the mixed material; step four: adding the filtered materials into skimmed milk powder, resistant dextrin, stevioside, magnesium stearate and 1% -4% of water, and stirring and mixing; step five: tabletting and forming, in the application file, antioxidant enzyme can be effectively supplemented, excessive free radicals can be removed, islet cells can be effectively protected, the damage of the free radicals can be avoided, the normal function of the islet cells can be further ensured, and endothelium-dependent vasodilation and diabetic microangiopathy can be improved.
Description
Technical Field
The invention relates to the technical field of diabetes treatment, in particular to a preparation method of a diabetes improving drug based on manganese type antioxidant enzyme.
Background
The consequence of hyperglycemia and high free fatty acid stimulation is an increase in the oxygen free radicals of the highly reactive molecules, which initiates the oxidative stress mechanism (tissue damage caused by a long-term imbalance between the production of highly reactive molecules and the antioxidant effect). The active molecules can directly oxidize and damage DNA, protein and lipid, and can also be used as functional molecular signals to activate various stress sensitive signal paths in cells, and the signal paths are closely related to insulin resistance and beta cell function impairment.
The islet-beta cells are also important targets of oxidative stress, and are sensitive to oxygen radicals due to low levels of antioxidant enzymes in the islet-beta cells. The oxygen free radicals can directly damage the islet beta cells, promote the islet beta cell apoptosis, and indirectly inhibit the beta cell function by influencing an insulin signal transduction pathway. Islet beta-cells are damaged, insulin secretion level is reduced, secretion peak is delayed, and blood sugar fluctuation is intensified, so that it is difficult to control rapid rise of postprandial blood sugar, and more obvious damage is caused to cells.
In the existing medicines, the medicine preparation can not be carried out aiming at oxidative stress and inflammatory reaction, and the antioxidant treatment can not be started from the root problem that the pancreatic islet-beta cells are oxidized and damaged, so that the occurrence and the development of diabetes and complications thereof can not be well prevented or intervened and regulated.
Disclosure of Invention
This section is for the purpose of summarizing some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. In this section, as well as in the abstract and the title of the invention of this application, simplifications or omissions may be made to avoid obscuring the purpose of the section, the abstract and the title, and such simplifications or omissions are not intended to limit the scope of the invention.
The present invention has been made in view of the above and/or the problems occurring in the existing diabetes improving drugs.
Therefore, the invention aims to provide a preparation method of a diabetes improving medicine based on manganese type antioxidant enzyme, which can effectively supplement antioxidant enzyme, eliminate excessive free radicals, effectively reduce oxidative stress and inflammatory reaction, effectively protect islet cells, avoid the invasion of free radicals, further ensure the normal function of the islet cells, and simultaneously improve endothelium-dependent vasodilatation and diabetic microangiopathy.
To solve the above technical problem, according to an aspect of the present invention, the present invention provides the following technical solutions:
a preparation method of a diabetes improving drug based on manganese type antioxidant enzyme comprises the following steps:
the method comprises the following steps: placing oat-beta glucan and sorbitol into a homogenizer for homogenization;
step two: adding fructus Momordicae Charantiae powder, stigma Maydis, radix Puerariae powder, folium Mori powder, herba Taraxaci powder, rhizoma Polygonati powder and superoxide dismutase MnSOD into the homogenized material, stirring and mixing;
step three: sieving the mixed materials with a 60-mesh sieve and filtering;
step four: adding the filtered materials into skimmed milk powder, resistant dextrin, stevioside, magnesium stearate and 1% -4% of water, and stirring and mixing;
step five: tabletting and molding at 10-30 deg.C and humidity of 40-55% RH.
As a preferable embodiment of the method for preparing a diabetes mellitus improving drug based on manganese type antioxidase according to the present invention, wherein: the medicine is prepared from the following materials in proportion:
38% of oat-beta glucan, 9% of sorbitol, 7% of bitter gourd powder, 8% of corn stigma, 6.7% of radix puerariae powder, 5% of mulberry leaf powder, 4% of dandelion powder, 4% of rhizoma polygonati powder, 10% of superoxide dismutase MnSOD, 5% of skimmed milk powder, 5% of resistant dextrin, 0.3% of stevioside and 1% of magnesium stearate.
Compared with the prior art: in the existing medicines, the medicine preparation can not be carried out aiming at oxidative stress and inflammatory reaction, and the anti-oxidation treatment can not be started from the root problem of oxidative damage of islet-beta cells, so that the occurrence and development of diabetes and complications thereof can not be well prevented or intervened and controlled, in the islet-B cells of a human body, the activities of anti-oxidation enzymes, namely SOD, catalase and glutathione peroxidase are relatively low, so that the islet-B cells are very sensitive to the damage mediated by oxygen radicals, and can not effectively eliminate excessive free radicals to reduce the oxidative stress and inflammatory reaction, and are not beneficial to promoting the repair of the islet cells, in the application document, the anti-oxidation enzymes can be effectively supplemented, the excessive free radicals can be eliminated, the oxidative stress and the inflammatory reaction can be effectively reduced, the islet cells can be effectively protected, and the damage of the free radicals can be avoided, thereby ensuring the normal function of islet cells and improving endothelium-dependent vasodilation and diabetic microangiopathy.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the present invention will be described in detail with reference to the accompanying drawings and detailed embodiments, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without inventive exercise. Wherein:
FIG. 1 is a schematic flow structure diagram of a preparation method of a diabetes improving drug based on manganese type antioxidase of the present invention.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are described in detail below.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways than those specifically described herein, and it will be apparent to those of ordinary skill in the art that the present invention may be practiced without departing from the spirit and scope of the present invention, and therefore the present invention is not limited to the specific embodiments disclosed below.
Next, the present invention will be described in detail with reference to the drawings, wherein for convenience of illustration, the cross-sectional view of the device structure is not enlarged partially according to the general scale, and the drawings are only examples, which should not limit the scope of the present invention. In addition, the three-dimensional dimensions of length, width and depth should be included in the actual fabrication.
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in detail with reference to the accompanying drawings.
The invention provides a preparation method of a diabetes improving medicine based on manganese type antioxidant enzyme, which comprises the following steps:
the method comprises the following steps: placing oat-beta glucan and sorbitol into a homogenizer for homogenization;
step two: adding fructus Momordicae Charantiae powder, stigma Maydis, radix Puerariae powder, folium Mori powder, herba Taraxaci powder, rhizoma Polygonati powder and superoxide dismutase MnSOD into the homogenized material, stirring and mixing;
step three: sieving the mixed materials with a 60-mesh sieve and filtering;
step four: adding the filtered materials into skimmed milk powder, resistant dextrin, stevioside, magnesium stearate and 1% -4% of water, and stirring and mixing;
step five: tabletting and molding at 10-30 deg.C and humidity of 40-55% RH.
Referring again to fig. 1, by way of example, the drug is prepared from the following materials:
38% of oat-beta glucan, 9% of sorbitol, 7% of bitter gourd powder, 8% of corn stigma, 6.7% of radix puerariae powder, 5% of mulberry leaf powder, 4% of dandelion powder, 4% of rhizoma polygonati powder, 10% of superoxide dismutase MnSOD, 5% of skimmed milk powder, 5% of resistant dextrin, 0.3% of stevioside and 1% of magnesium stearate.
While the invention has been described above with reference to an embodiment, various modifications may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In particular, the various features of the disclosed embodiments of the invention may be used in any combination, provided that no structural conflict exists, and the combinations are not exhaustively described in this specification merely for the sake of brevity and resource conservation. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed, but that the invention will include all embodiments falling within the scope of the appended claims.
Claims (2)
1. A preparation method of a diabetes improving medicine based on manganese type antioxidant enzyme is characterized in that: the preparation method of the diabetes improving medicine based on the manganese type antioxidant enzyme comprises the following steps:
the method comprises the following steps: placing oat-beta glucan and sorbitol into a homogenizer for homogenization;
step two: adding fructus Momordicae Charantiae powder, stigma Maydis, radix Puerariae powder, folium Mori powder, herba Taraxaci powder, rhizoma Polygonati powder and superoxide dismutase MnSOD into the homogenized material, stirring and mixing;
step three: sieving the mixed materials with a 60-mesh sieve and filtering;
step four: adding the filtered materials into skimmed milk powder, resistant dextrin, stevioside, magnesium stearate and 1% -4% of water, and stirring and mixing;
step five: tabletting and molding at 10-30 deg.C and humidity of 40-55% RH.
2. The method for preparing a manganese-based antioxidase-based diabetes mellitus-improving drug according to claim 1, wherein: the medicine is prepared from the following materials in proportion:
38% of oat-beta glucan, 9% of sorbitol, 7% of bitter gourd powder, 8% of corn stigma, 6.7% of radix puerariae powder, 5% of mulberry leaf powder, 4% of dandelion powder, 4% of rhizoma polygonati powder, 10% of superoxide dismutase MnSOD, 5% of skimmed milk powder, 5% of resistant dextrin, 0.3% of stevioside and 1% of magnesium stearate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269038.9A CN112826926A (en) | 2021-03-12 | 2021-03-12 | Preparation method of diabetes improving medicine based on manganese type antioxidant enzyme |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110269038.9A CN112826926A (en) | 2021-03-12 | 2021-03-12 | Preparation method of diabetes improving medicine based on manganese type antioxidant enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112826926A true CN112826926A (en) | 2021-05-25 |
Family
ID=75930130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110269038.9A Pending CN112826926A (en) | 2021-03-12 | 2021-03-12 | Preparation method of diabetes improving medicine based on manganese type antioxidant enzyme |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112826926A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583087A (en) * | 2004-05-22 | 2005-02-23 | 刘贤英 | Chinese health-care medicine for reducing blood sugar and preventing from diabete complication and its preparation |
| CN103202370A (en) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | Hypoglycemic tea and preparation method thereof |
| CN103285231A (en) * | 2013-05-13 | 2013-09-11 | 刘扬 | Medicine composition for diabetes adjunctive therapy and preparation method thereof |
| CN107468898A (en) * | 2017-09-11 | 2017-12-15 | 邹立影 | A kind of diabetic's special food and preparation method thereof |
| CN110251655A (en) * | 2019-07-31 | 2019-09-20 | 张先奇 | A kind of pharmaceutical composition and preparation method thereof for treating diabetes |
| CN111714573A (en) * | 2020-06-30 | 2020-09-29 | 广州贝塔健康生物科技有限公司 | Oat glucan particle for treating diabetes and preparation process thereof |
-
2021
- 2021-03-12 CN CN202110269038.9A patent/CN112826926A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1583087A (en) * | 2004-05-22 | 2005-02-23 | 刘贤英 | Chinese health-care medicine for reducing blood sugar and preventing from diabete complication and its preparation |
| CN103202370A (en) * | 2013-03-22 | 2013-07-17 | 安徽华佗国药股份有限公司 | Hypoglycemic tea and preparation method thereof |
| CN103285231A (en) * | 2013-05-13 | 2013-09-11 | 刘扬 | Medicine composition for diabetes adjunctive therapy and preparation method thereof |
| CN107468898A (en) * | 2017-09-11 | 2017-12-15 | 邹立影 | A kind of diabetic's special food and preparation method thereof |
| CN110251655A (en) * | 2019-07-31 | 2019-09-20 | 张先奇 | A kind of pharmaceutical composition and preparation method thereof for treating diabetes |
| CN111714573A (en) * | 2020-06-30 | 2020-09-29 | 广州贝塔健康生物科技有限公司 | Oat glucan particle for treating diabetes and preparation process thereof |
Non-Patent Citations (4)
| Title |
|---|
| 王文霞;贾伟平;: "锰超氧化物歧化酶与糖尿病慢性并发症", 上海医学, no. 04 * |
| 范强;杨丽霞;薛燕芳;白宇;姜良恩;刘铜华;: "2型糖尿病氧化应激与单味中药干预研究", 时珍国医国药, no. 07 * |
| 董吉林;陈明;申瑞玲;刘延奇;: "燕麦β-葡聚糖对STZ致Ⅱ型糖尿病小鼠胰岛素抵抗的影响", 郑州轻工业学院学报(自然科学版), no. 02 * |
| 金昕;陶枫;陆灏;沈远东;: "中药抗氧化在糖尿病中应用研究进展", 上海中医药大学学报, no. 04 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ayua et al. | Polyphenolic inhibition of enterocytic starch digestion enzymes and glucose transporters for managing type 2 diabetes may be reduced in food systems | |
| CN107094843A (en) | One kind control blood glucose health-caring biscuit and its manufacture method | |
| CN103610752A (en) | Functional food with hypoglycemic effect and preparation method thereof | |
| CN114632101B (en) | Cordyceps guangdongensis weight-losing lipid-lowering liver-protecting compound and preparation method and application thereof | |
| Arya et al. | Diosgenin: An ingress towards solving puzzle for diabetes treatment | |
| CN112826926A (en) | Preparation method of diabetes improving medicine based on manganese type antioxidant enzyme | |
| Chen et al. | Effects of Rosa roxburghii Tratt fruit and its active ingredients on glucose and lipid metabolism in type 2 diabetic mice. | |
| CN105145722A (en) | Fried dough twist assistant for lowering blood glucose and manufacturing method thereof | |
| Zhang et al. | Protective mechanism of Fagopyrum esculentum Moench. Bee pollen EtOH extract against type II diabetes in a high-fat diet/streptozocin-induced C57BL/6J mice | |
| CN114177247A (en) | Anticancer blood sugar-controlling inonotus obliquus pure powder tablet and preparation method and application thereof | |
| Gong et al. | Effects of crude flavonoids from tatary buckwheat on alloxan-induced oxidative stress in mice | |
| KP et al. | Okra Infusion Water Improving Stress Oxidative and Inflammatory Markers on Hyperglycemic Rats. | |
| KR101326002B1 (en) | Composition for use of reducing and controlling blood glucose for improving diabetes | |
| CN111494440A (en) | Extraction, purification and preparation technology of blood sugar reducing component saponin in caltrop, caltrop saponin extract and application | |
| CN111450136A (en) | Oyster and kudzu root composite particles and preparation method thereof | |
| CN107088206B (en) | Preparation method and application of cortex mori extract | |
| CN106901160B (en) | Food additive powder for reducing blood sugar, losing weight and protecting diabetic organs as well as preparation method and application thereof | |
| KR100697184B1 (en) | A functional food for a ginseng and mulberry and banaba and the producing method therof | |
| CN103549417B (en) | A kind of Bulbus Allii Cepae bitter gourd dispersible tablet and production technology thereof | |
| CN108578556A (en) | A kind of health products of reducing blood sugar and blood fat and preparation method thereof | |
| CN114451560A (en) | Dietary composition for diabetic patients and application thereof | |
| CN107582896A (en) | It is a kind of that there is preparation for reducing blood pressure and blood lipoid effect and preparation method thereof | |
| CN107625852A (en) | A kind of clearing heat and promoting diuresis stagnation resolvation stop-band Chinese medicine composition and its preparation technology and application | |
| CN106387795A (en) | Rhizoma polygonati odorati, mulberry leaf and royal jelly buccal tablets and production method | |
| CN102940182A (en) | Low energy propolis hard capsule preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210525 |
|
| WD01 | Invention patent application deemed withdrawn after publication |